Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Predicting Responses to Psychedelics: A Prospective Study
Eline Haijen, Mendel Kaelen, Leor Roseman, et al.
Frontiers in Pharmacology (2018) Vol. 9
Open Access | Times Cited: 317

Showing 1-25 of 317 citing articles:

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics
Robin Carhart‐Harris, Karl Friston
Pharmacological Reviews (2019) Vol. 71, Iss. 3, pp. 316-344
Open Access | Times Cited: 770
Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory
Leor Roseman, Eline Haijen, Kelvin Idialu-Ikato, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 9, pp. 1076-1087
Closed Access | Times Cited: 290
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies
Kristoffer A. A. Andersen, Robin Carhart‐Harris, David Nutt, et al.
Acta Psychiatrica Scandinavica (2020) Vol. 143, Iss. 2, pp. 101-118
Closed Access | Times Cited: 253
Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects
Jacob S. Aday, Alan K. Davis, Cayla M. Mitzkovitz, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 2, pp. 424-435
Open Access | Times Cited: 167
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 156
The Therapeutic Potential of Psilocybin
Henry Lowe, Ngeh J. Toyang, Blair Steele, et al.
Molecules (2021) Vol. 26, Iss. 10, pp. 2948-2948
Open Access | Times Cited: 153
Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials
Jacob S. Aday, Boris D. Heifets, Steven D. Pratscher, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1989-2010
Open Access | Times Cited: 146
Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness
Hannes Kettner, Fernando E. Rosas, Christopher Timmermann, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 143
Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression
Roberta Murphy, Hannes Kettner, Rick Zeifman, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 140
Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance
Max Wolff, Ricarda Evens, Lea J. Mertens, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 139
Self-blinding citizen science to explore psychedelic microdosing
Balázs Szigeti, Laura Kärtner, Allan Blemings, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 136
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects
A. Becker, Friederike Holze, Tanja Grandinetti, et al.
Clinical Pharmacology & Therapeutics (2021) Vol. 111, Iss. 4, pp. 886-895
Open Access | Times Cited: 130
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD
Alan K. Davis, Frederick S. Barrett, Sara So, et al.
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 437-446
Open Access | Times Cited: 129
Psychedelics alter metaphysical beliefs
Christopher Timmermann, Hannes Kettner, Chris Letheby, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 127
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing
Laura Kaertner, Michael B. Steinborn, Hannes Kettner, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 108
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience
Joseph Peill, Katie Trinci, Hannes Kettner, et al.
Journal of Psychopharmacology (2022) Vol. 36, Iss. 1, pp. 31-45
Open Access | Times Cited: 102
The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world
Rosalind Watts, Hannes Kettner, Dana Geerts, et al.
Psychopharmacology (2022) Vol. 239, Iss. 11, pp. 3461-3483
Open Access | Times Cited: 83
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
Federico Cavanna, Stephanie Müller, Laura Alethia de la Fuente, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 77
A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics
Christopher Timmermann, Prisca R. Bauer, Olivia Gosseries, et al.
Trends in Cognitive Sciences (2022) Vol. 27, Iss. 2, pp. 139-159
Open Access | Times Cited: 73
Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics
Otto Simonsson, Peter S. Hendricks, Richard Chambers, et al.
Journal of Affective Disorders (2023) Vol. 326, pp. 105-110
Open Access | Times Cited: 69
Case analysis of long-term negative psychological responses to psychedelics
Rebecka Bremler, Nancy Katati, Parvinder Shergill, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 42
Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
Sandeep M. Nayak, Hillary Jackson, Nathan D. Sepeda, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 40
Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression
Balázs Szigeti, Brandon Weiss, Fernando E. Rosas, et al.
Psychological Medicine (2024) Vol. 54, Iss. 8, pp. 1717-1724
Closed Access | Times Cited: 23
The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder
Adam W. Levin, Rafael Lancelotta, Nathan D. Sepeda, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0300501-e0300501
Open Access | Times Cited: 22
Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study
Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top